Table 2.

Ongoing clinical trials on DDR-related drugs with immunotherapy.

Research title	Tumor type	Drugs	Locations
Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.	Lung Neoplasm	Camrelizumab; Apatinib; Etoposide; Cisplatin	The 900th Hospital of Joint Logistic Support Force Fuzhou, Fujian, China
	Small Cell Lung Cancer
Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer	Biliary Tract Cancer	PD1 inhibitor; Cisplatin	Zhejiang Cancer Hospital Hangzhou, Zhejiang, China
Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT)	Head and Neck Squamous Cell Carcinoma	PD1 inhibitor; Cisplatin	Guopei Zhu Shanghai, China
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC	Oral Squamous Cell Carcinoma	Toripalimab; Albumin paclitaxel; Cisplatin	Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, Shanghai, China
A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)	Esophageal Squamous Cell Carcinoma	HLX10; Cisplatin	Ethics Committee of cancer hospital, Chinese academy of medical sciences, Beijing, Beijing, China et al.
Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas	Cervical Neuroendocrine Carcinoma	Camrelizumab; Cisplatin	Lei Li Beijing, Beijing, China
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC	Non-Squamous Non-Small Cell Neoplasm of Lung	Pemetrexed; Cisplatin (or carboplatin)	Regional Hospital Liberec
			Liberec, Czechia University Hospital Olomouc, Czechia et al.
Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC	Locally Advanced Head and Neck Squamous Cell Carcinoma	PD-1 inhibitor; Gemcitabine; Cisplatin	Fifth Affilliated Hospital of Sun Yat-sen University Zhuhai, Guangdong, China
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)	Urinary Bladder Cancer, Muscle-invasive	Pembrolizumab; Gemcitabine; Cisplatin	Scripps MD Anderson, California, United States et al.
Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma	Head and Neck Cancer	PD-1 inhibitor; Albumin Paclitaxel; Cisplatin	Hunan cancer Hospital Changsha, Hunan, China
	Squamous Cell Carcinoma
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/KEYNOTE-B99)	Small Cell Lung Cancer	Pembrolizumab; MK-4830; MK-5890	Banner MD Anderson Cancer Center Gilbert, Arizona, United States et al.
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)	Small Cell Lung Cancer	Pembrolizumab; Olaparib	Ironwood Cancer & Research Centers et al.
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)	Lung Neoplasms Carcinoma, Non-Small-Cell Lung	Pembrolizumab; Olaparib	University of South Alabama, Mitchell Cancer Institute, Alabama, United States et al.
Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy	Non-Small Cell Lung Cancer	Durvalumab; AZD9150; AZD6738	Research Site Duarte, California, United States et al.
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation	Metastatic Melanoma	Olaparib; Pembrolizumab	California Pacific Medical Center Research Institute, San Francisco, California, United States
Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma	Advanced Gastric Adenocarcinoma	Paclitaxel; Olaparib; Pembrolizumab	Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States